---
document_datetime: 2025-12-29 10:11:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-apotex.html
document_name: olanzapine-apotex.html
version: success
processing_time: 0.1032134
conversion_datetime: 2025-12-30 01:50:24.85526
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Olanzapine Apotex

[RSS](/en/individual-human-medicine.xml/67037)

##### Withdrawn

This medicine's authorisation has been withdrawn

olanzapine Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 12 August 2025, the European Commission withdrew the marketing authorisation for Olanzapine Apotex (olanzapine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Apotex Europe B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Olanzapine Apotex was granted marketing authorisation in the EU on 10 June 2010 for the treatment of schizophrenia and moderate to severe manic episode. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Olanzapine Apotex is a generic medicine of Zyprexa. There are other generic medicinal products of Zyprexa authorised and marketed in the EU.

Olanzapine Apotex : EPAR - Summary for the public

English (EN) (67.64 KB - PDF)

**First published:** 23/06/2010

**Last updated:** 23/06/2010

[View](/en/documents/overview/olanzapine-apotex-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-632)

български (BG) (170.21 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/bg/documents/overview/olanzapine-apotex-epar-summary-public_bg.pdf)

español (ES) (130.99 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/es/documents/overview/olanzapine-apotex-epar-summary-public_es.pdf)

čeština (CS) (155.84 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/cs/documents/overview/olanzapine-apotex-epar-summary-public_cs.pdf)

dansk (DA) (130.5 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/da/documents/overview/olanzapine-apotex-epar-summary-public_da.pdf)

Deutsch (DE) (130.82 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/de/documents/overview/olanzapine-apotex-epar-summary-public_de.pdf)

eesti keel (ET) (127.95 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/et/documents/overview/olanzapine-apotex-epar-summary-public_et.pdf)

ελληνικά (EL) (171.42 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/el/documents/overview/olanzapine-apotex-epar-summary-public_el.pdf)

français (FR) (131.04 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/fr/documents/overview/olanzapine-apotex-epar-summary-public_fr.pdf)

italiano (IT) (131.27 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/it/documents/overview/olanzapine-apotex-epar-summary-public_it.pdf)

latviešu valoda (LV) (154.8 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/lv/documents/overview/olanzapine-apotex-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (154.83 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/lt/documents/overview/olanzapine-apotex-epar-summary-public_lt.pdf)

magyar (HU) (152.43 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/hu/documents/overview/olanzapine-apotex-epar-summary-public_hu.pdf)

Malti (MT) (157.18 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/mt/documents/overview/olanzapine-apotex-epar-summary-public_mt.pdf)

Nederlands (NL) (129.89 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/nl/documents/overview/olanzapine-apotex-epar-summary-public_nl.pdf)

polski (PL) (157.28 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/pl/documents/overview/olanzapine-apotex-epar-summary-public_pl.pdf)

português (PT) (130.16 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/pt/documents/overview/olanzapine-apotex-epar-summary-public_pt.pdf)

română (RO) (153.89 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/ro/documents/overview/olanzapine-apotex-epar-summary-public_ro.pdf)

slovenčina (SK) (154.78 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/sk/documents/overview/olanzapine-apotex-epar-summary-public_sk.pdf)

slovenščina (SL) (151.28 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/sl/documents/overview/olanzapine-apotex-epar-summary-public_sl.pdf)

Suomi (FI) (129.84 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/fi/documents/overview/olanzapine-apotex-epar-summary-public_fi.pdf)

svenska (SV) (129.75 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

23/06/2010

[View](/sv/documents/overview/olanzapine-apotex-epar-summary-public_sv.pdf)

## Product information

Olanzapine Apotex : EPAR - Product Information

English (EN) (1.1 MB - PDF)

**First published:** 23/06/2010

**Last updated:** 09/03/2023

[View](/en/documents/product-information/olanzapine-apotex-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-648)

български (BG) (1.15 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/bg/documents/product-information/olanzapine-apotex-epar-product-information_bg.pdf)

español (ES) (1.16 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/es/documents/product-information/olanzapine-apotex-epar-product-information_es.pdf)

čeština (CS) (1.16 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/cs/documents/product-information/olanzapine-apotex-epar-product-information_cs.pdf)

dansk (DA) (997.94 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/da/documents/product-information/olanzapine-apotex-epar-product-information_da.pdf)

Deutsch (DE) (1.22 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/de/documents/product-information/olanzapine-apotex-epar-product-information_de.pdf)

eesti keel (ET) (1.12 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/et/documents/product-information/olanzapine-apotex-epar-product-information_et.pdf)

ελληνικά (EL) (1.44 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/el/documents/product-information/olanzapine-apotex-epar-product-information_el.pdf)

français (FR) (1.26 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/fr/documents/product-information/olanzapine-apotex-epar-product-information_fr.pdf)

hrvatski (HR) (1.1 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/hr/documents/product-information/olanzapine-apotex-epar-product-information_hr.pdf)

íslenska (IS) (988.42 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/is/documents/product-information/olanzapine-apotex-epar-product-information_is.pdf)

italiano (IT) (990.75 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/it/documents/product-information/olanzapine-apotex-epar-product-information_it.pdf)

latviešu valoda (LV) (1.29 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/lv/documents/product-information/olanzapine-apotex-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.27 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/lt/documents/product-information/olanzapine-apotex-epar-product-information_lt.pdf)

magyar (HU) (1.19 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/hu/documents/product-information/olanzapine-apotex-epar-product-information_hu.pdf)

Malti (MT) (1.34 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/mt/documents/product-information/olanzapine-apotex-epar-product-information_mt.pdf)

Nederlands (NL) (1.72 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/nl/documents/product-information/olanzapine-apotex-epar-product-information_nl.pdf)

norsk (NO) (919.31 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/no/documents/product-information/olanzapine-apotex-epar-product-information_no.pdf)

polski (PL) (1.36 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/pl/documents/product-information/olanzapine-apotex-epar-product-information_pl.pdf)

português (PT) (998.77 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/pt/documents/product-information/olanzapine-apotex-epar-product-information_pt.pdf)

română (RO) (1.25 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/ro/documents/product-information/olanzapine-apotex-epar-product-information_ro.pdf)

slovenčina (SK) (1.24 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/sk/documents/product-information/olanzapine-apotex-epar-product-information_sk.pdf)

slovenščina (SL) (1.18 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/sl/documents/product-information/olanzapine-apotex-epar-product-information_sl.pdf)

Suomi (FI) (1003.99 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

09/03/2023

[View](/fi/documents/product-information/olanzapine-apotex-epar-product-information_fi.pdf)

**Latest procedure affecting product information:** IAIN/0048 08/03/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Olanzapine Apotex : EPAR - All Authorised presentations

English (EN) (32.64 KB - PDF)

**First published:** 23/06/2010

**Last updated:** 14/10/2011

[View](/en/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-972)

български (BG) (58.2 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/bg/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_bg.pdf)

español (ES) (32.86 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/es/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_es.pdf)

čeština (CS) (39.32 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/cs/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (34.99 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/da/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (32.96 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/de/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (33.28 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/et/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (58.37 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/el/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_el.pdf)

français (FR) (34.85 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/fr/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (32.78 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/it/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (53.7 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/lv/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (51.69 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/lt/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (41.97 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/hu/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (48.77 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/mt/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (34.76 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/nl/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_nl.pdf)

polski (PL) (50.09 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/pl/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_pl.pdf)

português (PT) (36.45 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/pt/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_pt.pdf)

română (RO) (47.6 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/ro/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (51.21 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/sk/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.67 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/sl/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (34.72 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/fi/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (32.89 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

14/10/2011

[View](/sv/documents/all-authorised-presentations/olanzapine-apotex-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Olanzapine Apotex Active substance olanzapine International non-proprietary name (INN) or common name olanzapine Therapeutic area (MeSH)

- Schizophrenia
- Bipolar Disorder

Anatomical therapeutic chemical (ATC) code N05AH03

### Pharmacotherapeutic group

Psycholeptics

### Therapeutic indication

Olanzapine is indicated for the treatment of schizophrenia.

Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.

Olanzapine is indicated for the treatment of moderate to severe manic episode.

In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

## Authorisation details

EMA product number EMEA/H/C/001178

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Apotex Europe BV

Baarnsche Dijk 1

Marketing authorisation issued 10/06/2010 Withdrawal of marketing authorisation 12/08/2025 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Olanzapine Apotex : EPAR - Procedural steps taken and scientific information after authorisation

Reference Number: EMA/175903/2020

English (EN) (1.63 MB - PDF)

**First published:** 25/02/2011

**Last updated:** 09/03/2023

[View](/en/documents/procedural-steps-after/olanzapine-apotex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Olanzapine Apotex : EPAR - Public assessment report

English (EN) (240.18 KB - PDF)

**First published:** 23/06/2010

**Last updated:** 23/06/2010

[View](/en/documents/assessment-report/olanzapine-apotex-epar-public-assessment-report_en.pdf)

CHMP positive summary of opinion for Olanzapine Apotex

Adopted

Reference Number: EMA/148993/2010

English (EN) (69.99 KB - PDF)

**First published:** 19/03/2010

**Last updated:** 19/03/2010

[View](/en/documents/smop-initial/chmp-positive-summary-opinion-olanzapine-apotex_en.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 23/09/2025

## Share this page

[Back to top](#main-content)